JP2011201801A - Fatty liver preventive and/or inhibitor - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide medicine, food and drink, and animal feed effective in prevention and/or inhibition of a fatty liver.SOLUTION: The fatty liver preventive and/or inhibitor contains the fungal body of Lactobacillus helveticus as an active ingredient.

Description

  TECHNICAL FIELD The present invention relates to a fatty liver prevention and / or inhibitor containing Lactobacillus helveticus as an active ingredient, and a food and drink and a feed containing the fatty liver prevention and / or inhibitor.

  Fatty liver is a general term for diseases in which neutral fat is excessively deposited in the liver and causes liver damage. Normally, the liver contains about 3 to 5% of lipid in the liver, but when the amount of liver lipid exceeds 10%, fatty liver is diagnosed. Fatty liver is known to develop due to various factors such as overeating, lack of exercise, excessive intake of alcohol, and viral infection. A simple diagnosis of liver disease may be evaluated with blood markers such as GPT (glutamate-pyruvate transamylase) and GOT (glutamate-oxaloacetate transamylase), which are known to be abundant in the liver. It is common. However, in fatty livers, these blood markers often vary slightly, and in most cases there is no subjective symptom, so discovery tends to be delayed.

  In recent years, the number of nonalcoholic fatty liver disease (NAFLD) patients is increasing worldwide with the increase of obese people. NAFLD excludes fatty liver that has no history of alcohol consumption and has obvious causes such as viral hepatitis and autoimmune hepatitis. NAFLD resulting from lifestyle is said to be a liver lesion of metabolic syndrome, and is considered to be the most frequently occurring liver disease and corresponds to 10 to 30% of adults (for example, Non-Patent Document 1). NAFLD also includes non-progressive simple fatty liver, cirrhosis, and nonalcoholic steatohepatitis (NASH) that can progress to liver carcinogenesis. NASH is based on fatty liver formation, and pathological conditions are formed by further induction of oxidative stress and inflammatory cytokines. Although it is thought that the number of NASH patients will continue to increase in the future, standard treatments have not been established at present, so it is very important to work on prevention and improvement of fatty liver on a daily basis to maintain health. It is considered important.

  In order to prevent and improve fatty liver, it is necessary to maintain a good balance between energy intake and consumption by conducting daily health management such as thorough daily nutrition management and appropriate exercise. Become. However, in an environment surrounding a busy modern society, it is not easy to break away from irregular life rhythms, biased nutrition, and lack of exercise. Therefore, a method that can expect a sufficient effect and can be practiced easily and safely is required.

  A method for preventing and treating fatty liver, comprising an effective amount of conjugated diene linoleic acid together with a pharmaceutical carrier or a food carrier, a composition for inhibiting liver fat accumulation (for example, Patent Document 1), a highly unsaturated fatty acid An oil / fat composition (for example, Patent Document 2), comprising at least one amino acid having a glucagon-secreting action, xanthine derivative, wherein the oil-and-fat contains an egg yolk lipid containing about 25 to about 70% by weight of phospholipid. A composition containing at least one kind and at least one kind of thiamine compound (for example, Patent Document 3), and crude soybean lecithin produced in the process of producing fats and oils from soybeans are fractionated with an organic solvent, an adsorbent, an ion exchange resin, etc. The obtained crude soybean lecithin fraction having an effect of inhibiting the synthesis of liver neutral fat and the crude soybean lecithin fraction were blended with known raw materials. Techniques such as food and drink, animal feed or medicine (for example, Patent Document 4) are disclosed.

In addition, visceral fat accumulation inhibitor (for example, Patent Document 5) and visceral fat reducing agent (for example, Patent Document 6) containing Lactobacillus helveticus as an active ingredient, blood containing a culture of Lactobacillus genus lactic acid bacteria, and the like as active ingredients A medium adiponectin concentration increase promoting and / or decreasing inhibitor is disclosed (for example, Patent Document 7).
The method further comprises the step of examining the ability to adsorb cholic acid and the ability to convert or decompose cholic acid, and selecting a strain excellent in the ability to adsorb cholic acid and to convert or / degrade cholic acid. A method for screening lactic acid bacteria having an action of reducing cholesterol in the body (for example, Patent Document 8) and a process of selecting a strain excellent in the ability to reduce cholesterol in micelles of lactic acid bacteria and having an action of reducing cholesterol in vivo. A screening method for lactic acid bacteria has been disclosed (for example, Patent Document 9).

Japanese Patent Laid-Open No. 11-79987 Japanese Patent Laid-Open No. 10-237480 Japanese Patent Laid-Open No. 10-158170 JP-A-10-84879 JP 2008-63227 A JP 2008-214253 A JP 2008-63289 A JP 2004-208577 A JP 2006-217879 A

Reiko Hashimoto, Latest Medicine Vol. 63, No. 9, 1672, 2008

Although various substances are disclosed in Patent Documents 1 to 4, there is no suggestion or description regarding Lactobacillus helveticus.
Patent Documents 5 and 6 disclose visceral fat accumulation inhibitor and visceral fat reducing agent containing Lactobacillus helveticus as an active ingredient, but relate to adipose tissue such as the mesentery, perirenal and retroabdominal wall, There is no disclosure of an effect on fatty liver disease in which neutral fat is excessively deposited in a liver that is not an adipose tissue and causes liver damage. Furthermore, accumulation of fat in the liver is said to be a disease state that is said to be fatty degeneration and causes liver damage when symptoms progress, but adipose tissues such as the mesentery, surrounding kidneys, and the retroabdominal wall are originally organs that accumulate fat. For this reason, accumulation of fat is not an abnormal (disease state) unless it is excessive, and these are considered to be completely different.
Patent Document 7 discloses a blood adiponectin concentration increase promoting and / or decreasing inhibitor comprising, as an active ingredient, a culture of Lactobacillus lactic acid bacteria, etc., which relates to blood adiponectin concentration, and is related to thrombosis, sugar It is related to the future development of cardiovascular diseases such as metabolic abnormalities, and no effect on fatty liver disease is disclosed.
Patent Documents 8 and 9 disclose a cholesterol lowering effect by lactic acid bacteria, but the effect is only a reduction of cholesterol by an in vitro test, and a decrease in both cholesterol and triglyceride (neutral lipid) in the liver is observed. This is different from the present invention. In addition, it is thought that the effect until fatty liver prevention and suppression is not acquired only by reduction of cholesterol.

  It is an object of the present invention to provide an agent effective in preventing or suppressing fatty liver, a food and drink and a feed containing the agent by reducing liver cholesterol and triglycerides by Lactobacillus helveticus. .

Accordingly, the present invention is an invention having any of the following configurations.
(1) A fatty liver preventive and / or inhibitor comprising as an active ingredient a bacterial body of Lactobacillus helveticus (Lactobacillus helveticus).
(2) A fatty liver preventive and / or suppressant comprising a culture of Lactobacillus helveticus as an active ingredient.
(3) A fatty liver preventive and / or suppressant comprising the culture supernatant of Lactobacillus helveticus as an active ingredient.
(4) The fatty liver preventive and / or suppressant according to (2) above, wherein the culture is a dairy product.
(5) The fatty liver prevention and / or inhibitor according to (4) above, wherein the dairy product is any of cheese, fermented milk, and dairy lactic acid bacteria beverages.
(6) The fatty liver prevention and / or inhibitor according to any one of (1) to (5) above, wherein Lactobacillus helveticus is SBT2171 strain (FERM BP-5445).
(7) A food and drink for fatty liver prevention and / or suppression comprising the fatty liver prevention and / or inhibitor according to any one of (1) to (6) above.
(8) A diet for preventing and / or inhibiting fatty liver, comprising the fatty liver preventing and / or inhibitor according to any one of (1) to (6) above.

Another aspect of the present invention includes any of the following configurations.
(A) A method for preventing and / or inhibiting fatty liver, comprising administering a bacterial body of Lactobacillus helveticus.
(B) A method for preventing and / or suppressing fatty liver, comprising administering a culture of Lactobacillus helveticus.
(C) A method for preventing and / or inhibiting fatty liver, comprising administering a culture supernatant of Lactobacillus helveticus.
(D) The method for preventing and / or inhibiting fatty liver according to (b) above, wherein the culture is a dairy product.
(E) The method for preventing and / or inhibiting fatty liver according to (d) above, wherein the dairy product is any of cheese, fermented milk, and dairy lactic acid bacteria beverages.
(F) The method for preventing and / or inhibiting fatty liver according to any one of the above (a) to (e), wherein Lactobacillus helveticus is SBT2171 strain (FERM BP-5445).

  Lactobacillus helveticus of the present invention (Lactobacillus helveticus) as an active ingredient, preventing and / or inhibiting fatty liver, food and drink containing fatty liver prevention and / or inhibitor, and feed, suppress fat accumulation in the liver, It is effective for prevention and / or suppression of fatty liver.

It is the figure which showed the GPT density | concentration of the 4th week and the 8th week when the culture of Lactobacillus helveticus (Lactobacillus helveticus) is mixed with a feed and administered to a rat. It is the figure which showed the GOT density | concentration of the 4th week and the 8th week when the culture of Lactobacillus helveticus (Lactobacillus helveticus) is mixed with a feed and administered to a rat. It is the figure which showed the liver cholesterol of the 8th week when the culture of Lactobacillus helveticus (Lactobacillus helveticus) is mixed with a feed and administered to a rat. It is the figure which showed the liver triglyceride of the 8th week when the culture of Lactobacillus helveticus (Lactobacillus helveticus) is mixed with a feed and administered to a rat. It is the figure which showed the liver cholesterol of the 4th week at the time of mixing the culture of Lactobacillus helveticus (Lactobacillus helveticus) with the cholesterol addition feed, and administering to a rat. It is the figure which showed the liver triglyceride of the 4th week when the culture of Lactobacillus helveticus (Lactobacillus helveticus) is mixed with a cholesterol addition feed, and is administered to a rat. It is the figure which showed the amount of excretion in the feces of the 4th week when the culture of Lactobacillus helveticus (Lactobacillus helveticus) is mixed with a cholesterol addition feed, and is administered to a rat.

Lactobacillus helveticus (Lactobacillus helveticus) can be used for the prevention and control of fatty liver. ), SBT2196 (FERM P-11676), SBT0064 (FERM P-21079), SBT0402 (FERM P-21559) and the like are preferable, but not particularly limited.
Lactobacillus helveticus can be cultured according to a conventional method for lactic acid bacteria culture. As the culture medium, various media such as a milk medium or a medium containing a milk component and a semi-synthetic medium not containing the milk medium can be used. Examples of such a medium include reduced skim milk medium.
The cells isolated from the obtained culture by means of collection such as centrifugation can be used as they are as the active ingredient of the present invention. Concentrated, dried, freeze-dried cells, etc. can be used, or dead cells can be formed by heat drying.
Not only those that are purely isolated as cells, but also cultures, suspensions, other cell-containing materials, and cytoplasm and cell wall fractions obtained by treating cells with enzymes or physical means should be used. it can.
Examples of cultures include MRS medium (DIFCO), which is a synthetic medium, and cultures that use medium commonly used for cultivating lactic acid bacteria, such as reduced skim milk medium, as well as cheese, fermented milk, and dairy products. Examples of dairy products such as lactic acid bacteria beverages are not particularly limited.
Furthermore, a culture supernatant prepared by removing milk protein precipitates and bacterial cell components from the obtained culture using methods such as centrifugation and filtration can also be used. Since it is a supernatant with a low solid content, the range of application to foods and drinks is widened. For example, the culture supernatant can be prepared by centrifuging the reduced skim milk culture at 5,000 rpm for 10 minutes.

  In the preparation of the preparation, excipients, stabilizers, corrigents, and the like that are permitted in preparation can be mixed as appropriate and concentrated, freeze-dried, or dried by heating to form dead cells. These dried products, concentrates, and pastes are also included. In addition, as long as it does not interfere with fatty liver prevention and / or suppression action of Lactobacillus helveticus (Lactobacillus helveticus), excipients, binders, disintegrants, lubricants, flavoring agents, suspending agents, coating agents, It can also be formulated by mixing other arbitrary drugs. The dosage form can be tablets, capsules, granules, powders, powders, syrups, etc., and these are preferably administered orally.

  The fatty liver prevention and / or inhibitor of the present invention may be incorporated into any food or drink, and may be added to the raw material during the production process of the food or drink. Examples of food and drink include dairy products such as cheese, fermented milk, dairy lactic acid bacteria beverages, lactic acid bacteria beverages, butter and margarine, beverages such as dairy beverages, fruit juice beverages and soft drinks, eggs such as jelly, candy, pudding and mayonnaise Processed products, confectionery and breads such as butter cake, and various types of powdered milk, infant foods, nutritional compositions and the like can be mentioned, but are not particularly limited.

  Furthermore, the fatty liver preventive and / or inhibitor of the present invention can be added to the feed. Like the said food-drinks, you may mix | blend with what kind of feed, and may add to a raw material during the manufacturing process of a feed.

  Lactobacillus helveticus (Lactobacillus helveticus) is blended and used in fatty liver prophylaxis and / or inhibitors, food and drink for fatty liver prophylaxis and / or suppression, feeds and other processed materials. In this case, the mixing ratio of Lactobacillus helveticus is not particularly limited, and may be appropriately adjusted according to the ease of production and the preferred daily dose. It is determined individually in consideration of the symptom, age, etc. of the subject of administration, but in the case of normal adults, 10 to 200 g of Lactobacillus helveticus culture etc., or 0.1 to What is necessary is just to adjust a compounding quantity etc. so that 5,000 mg can be ingested. A desired effect can be exhibited by ingesting in this way.

  Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples. However, these are merely illustrative and the present invention is not limited thereto.

The raw milk was sterilized by heating (75 ° C., 15 seconds), cooled to 30 ° C., and 0.01% calcium chloride was added. Furthermore, 0.7% of commercially available lactic acid bacteria starter (LD starter, Christian Hansen) and Lactobacillus helveticus SBT2171 strain (FERM BP-5445) 1% are added, and rennet 0.003% is further added, and milk is added. Solidified. The curd thus obtained was cut, stirred until the pH was 6.2 to 6.1, and whey was discharged to obtain curd grains. Then, the curd grains were filled and pressed, further salted, and aged at 10 ° C. to prepare gouda cheese type hard natural cheese. The hard natural cheese (aged for 6 months) was minced using a mincer (GM-DX, manufactured by Nippon Carrier Co., Ltd.) and freeze-dried. Then, it refined | miniaturized with the coffee mill and the cheese powder which is a culture of Lactobacillus helveticus was obtained.
[Test Example 1]

(Confirmation of fatty liver prevention and / or suppression effect)
Using cheese powder, which is a culture of Lactobacillus helveticus obtained in Example 1, the effect of preventing and / or suppressing fatty liver was confirmed. For animal experiments, 4-week-old Fischer male rats were used. There are two groups: one group with 6 animals, a group fed with a high-fat diet formulated with a culture (cultured diet group), and a group administered with a high-fat diet formulated with casein and 20% milk fat (control diet group) I did it. The two feeds were designed with the fat content, protein content, and main mineral content based on the results of cheese component analysis (see Table 1).

  In the animal experiment, after 1 week of pre-feeding, the animals were divided into two groups, and a control diet and a culture diet were fed up to the 8th week. Blood was collected at 4th and 8th weeks, and GOT and GPT concentrations as liver injury markers were measured (Fuji Dry Chem 7000v, Fuji Film Co., Ltd.). In addition, dissection was performed on the last day of breeding, the liver was collected, liver lipid was extracted from a part of the liver according to the method of Folch et al., And the liver lipid content was measured.

There were no differences in food intake and body weight changes between the control food group and the culture-containing food group. In addition, there was no difference in the concentrations of GPT and GOT, which are liver injury markers, between the two groups (FIGS. 1 and 2). When the lipid content in the liver was measured, both cholesterol and triglyceride (Fuji Dry Chem 7000v, Fuji Film Co., Ltd.) were significantly decreased in the culture-containing diet group (FIGS. 3 and 4).
Therefore, the effect | action which suppresses the fat accumulation of the previous stage which gives damage to a liver is recognized, and it is clear that it has the prevention and suppression effect of fatty liver.
[Test Example 2]

(Confirmation of fatty liver prevention and / or suppression in dietary hypercholesterolemia)
Using cholesterol-added feed in which cheese powder, which is a culture of Lactobacillus helveticus obtained in Example 1, was mixed, the fatty liver prevention and / or inhibitory action was confirmed. For animal experiments, 4-week-old male Fischer rats were used. One group consists of 6 animals, a group administered with a high fat diet containing 20% casein and milk fat (control diet group), a group administered with a high fat diet formulated with a culture (culture group), and half of the culture. Three groups (group 1/2 cultures) to which the high fat diet formulated was administered were set. All feeds were mixed with 0.5% cholesterol and 0.15% sodium cholate to make hypercholesterolemia-induced feeds. The three feeds were designed with the protein content, fat content, and main mineral content based on the results of cheese component analysis (see Table 2).

  In the animal experiment, after 1 week of preliminary breeding, the animals were divided into 3 groups, and a control diet, a culture combination diet, and a half culture combination diet were fed up to the 4th week. In the 4th week, it was transferred to a metabolic cage and 3 days' worth of feces was collected. The obtained feces were freeze-dried and then crushed. After reacting with concentrated hydrochloric acid, crude fat in the feces was extracted with ether, and the weight of evaporated ether was measured. Further, dissection was performed on the last day of the breeding, and the liver lipid content was measured by the same method as in Test Example 1.

There was no difference between the three groups in changes in food intake and body weight. When the lipid content in the liver was measured, both cholesterol and triglyceride were significantly decreased in the culture-containing diet group and the culture 1 / 2-containing diet group as compared to the control diet group (FIGS. 5 and 6). Fecal lipid excretion increased in the culture-containing diet group compared to the control diet group, but the culture 1 / 2-containing diet group showed no difference from the control diet group (FIG. 7).
Therefore, even in the situation of dietary hypercholesterolemia, fat accumulation in the liver is suppressed, and there is an effect of preventing and suppressing fatty liver.

  After sterilizing 13% reduced skim milk medium at 95 ° C for 30 minutes, inoculated with Lactobacillus helveticus SBT2171 strain (FERM BP-5445), cultured at 37 ° C for 16 hours, It was freeze-dried to obtain a culture powder of Lactobacillus helveticus SBT2171 strain (FERM BP-5445). This can be used as a fatty liver preventive and / or inhibitor as it is.

  The MRS (DIFCO) culture of Lactobacillus helveticus strain SBT2171 (FERM BP-5445) was centrifuged at 4 ° C and 7,000 rpm for 15 minutes, and then washed with sterile water and centrifuged three times. To obtain washed cells. The washed cells were freeze-dried to obtain cell powder. This can be used as a fatty liver preventive and / or inhibitor as it is.

  4 parts of skim milk powder were mixed with 1 part of the cell powder prepared in Example 3 and 1 g of this mixed powder was tableted by a conventional method using a tableting machine, and Lactobacillus helveticus SBT2171 strain (FERM A tablet containing 200 mg of BP-5445) was prepared.

10% reduced skim milk medium is sterilized at 115 ° C for 15 minutes, then inoculated with Lactobacillus helveticus SBT2171 strain (FERM BP-5445), cultured at 37 ° C for 16 hours,
A skim milk culture was prepared. Fermented mix (16% nonfat dry milk + 3% glucose) sterilized at 100 ° C. for 10 minutes was inoculated and fermented at 39 ° C. for 10 hours to obtain fermented milk for fatty liver prevention and / or suppression. The viable cell count of Lactobacillus helveticus SBT2171 strain (FERM BP-5445) was 5 × 10 ⁸ cfu / g.

  Lactobacillus helveticus SBT2171 strain (FERM BP-5445) cultivated in 10% reduced skim milk medium for 90 minutes at 95 ° C for 10 minutes, fermented mix (16% skimmed milk powder + 3% glucose) 10% Was added and cultured at 35 ° C. for 20 hours. 10 g of this culture was mixed with 40 g of isomerized sugar (BRIX 15%) to obtain a dairy lactic acid bacteria beverage for prevention and / or suppression of fatty liver.

  Reduced skim milk medium (13% by weight nonfat dry milk, 0.5% yeast extract) was sterilized at 95 ° C for 30 minutes, then inoculated with Lactobacillus helveticus SBT2171 strain (FERM BP-5445) and 16 ° C at 16 ° C. After culturing for a period of time, the obtained culture was centrifuged at 5,000 rpm for 20 minutes to obtain a culture supernatant from which the precipitate was removed. This can be used as a fatty liver preventive and / or inhibitor as it is.

  To 50 g of cheese powder, which is a culture of Lactobacillus helveticus SBT2171 strain (FERM BP-5445) obtained in Example 1, 40 g of an equal mixture of vitamin C and citric acid, 100 g of granulated sugar, corn starch, 60 g of a mixture of equal amounts of lactose was added and mixed. The mixture was packed in a stick-shaped bag to obtain a health food for preventing and / or suppressing fatty liver.

  Soybean cake 12 kg, skim milk powder 14 kg, soybean oil 4 kg, corn oil 2 kg, palm oil 23.2 kg, corn starch 14 kg, wheat flour 9 kg, bran 2 kg, vitamin mixture 5 kg, cellulose 2.8 kg, mineral mixture 2 kg, 120 ℃, 4 Sterilized for a minute and mixed with 10 kg of Lactobacillus helveticus SBT2171 strain (FERM BP-5445) obtained in Example 1 to produce a feed for preventing and / or suppressing fatty liver.

  After sterilizing a 13% reduced skim milk medium at 95 ° C for 30 minutes, inoculated with Lactobacillus helveticus strain SBT2195 (FERM P-11538), cultured at 37 ° C for 16 hours, It was freeze-dried to obtain a culture powder of Lactobacillus helveticus SBT2195 strain (FERM P-11538). This can be used as a fatty liver preventive and / or inhibitor as it is.

  The MRS (DIFCO) culture of Lactobacillus helveticus SBT2196 (FERM P-11676) was centrifuged at 7,000 rpm for 15 minutes at 4 ° C, and then washed with sterile water and centrifuged three times. To obtain washed cells. The washed cells were freeze-dried to obtain cell powder. This can be used as a fatty liver preventive and / or inhibitor as it is.

After sterilizing 10% reduced skim milk medium at 115 ° C. for 15 minutes, inoculated with Lactobacillus helveticus SBT0064 strain (FERM P-21079), and cultured at 37 ° C. for 16 hours.
A skim milk culture was prepared. Fermented mix (16% nonfat dry milk + 3% glucose) sterilized at 100 ° C. for 10 minutes was inoculated and fermented at 39 ° C. for 10 hours to obtain fermented milk for prevention and / or suppression of fatty liver. The viable cell count of Lactobacillus helveticus SBT0064 strain (FERM P-21079) was 7 × 10 ⁸ cfu / g.

  The raw milk was sterilized by heating (75 ° C., 15 seconds), cooled to 30 ° C., and 0.01% calcium chloride was added. Furthermore, 0.7% of commercially available lactic acid bacteria starter (LD starter, Christian Hansen) and 1% of Lactobacillus helveticus SBT0402 strain (FERM P-21559) were added, and 0.003% of rennet was further added. Solidified. The curd thus obtained was cut, stirred until the pH was 6.2 to 6.1, and whey was discharged to obtain curd grains. Then, the curd grains were molded and pressed, further salted, and aged at 10 ° C. to prepare Gouda cheese type hard natural cheese for preventing and / or suppressing fatty liver.

  INDUSTRIAL APPLICABILITY The present invention can prevent or suppress fatty liver using as an active ingredient a bacterial body of Lactobacillus helveticus. Furthermore, as a fatty liver prevention and / or inhibitor, in addition to foods and drinks, various milk powders, it can be added to infant foods, nutritional compositions, feeds, and the like.

FERM BP-5445
FERM P-11538
FERM P-11676
FERM P-21079
FERM P-21559

[Reference to deposited biological materials]
(1) SBT2171
(A) Name and address of the depository organization depositing the biological material The Institute of Biotechnology, National Institute of Advanced Industrial Science and Technology (currently the National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center)
Tsukuba City, Ibaraki Prefecture, Japan, 1st East, 1st Street, 1st Central, 6th (zip code 305-8566)
Date of deposit of biological materials at Loi depository on June 22, 1994 (original deposit date)
March 6, 1996 (Date of transfer to deposit under the Budapest Treaty by original deposit)
The deposit number assigned by the depository in Hai for the deposit
FERM BP-5445
(2) SBT2195
The name and address of the depository organization depositing the biological material The Institute of Microbial Industrial Technology, National Institute of Advanced Industrial Science and Technology (currently the National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center)
Tsukuba City, Ibaraki Prefecture, Japan, 1st East, 1st Street, 1st Central, 6th (zip code 305-8566)
Date of deposit of biological materials at the depository in Loi June 18, 1990 The deposit number assigned by the depository in high on the deposit
FERM P-11538
(3) SBT2196
(A) Name and address of the depository that deposited the biological material The date on which the deposit was made on August 23, 1990, when the biological material was deposited at the same depository in (2) above.
FERM P-11676
(4) SBT0064
The name and address of the depository that deposited the biological material AIST National Institute of Advanced Industrial Science and Technology Patent Biological Deposit Center 1-chome, East 1-chome, Tsukuba City, Ibaraki Prefecture, Japan 6 (zip code 305-8566)
Date of deposit of biological materials at the depository of Loi November 8, 2006 Deposit number assigned by the depository of hi to the deposit
FERM P-21079
(5) SBT0402
(A) Name and address of the depository that deposited the biological material The date of deposit of the biological material at the depository in the same Loi as in (4) above The deposit number assigned to the deposit by the depositary on March 28, 2008
FERM P-21559

Claims (8)

An agent for preventing and / or inhibiting fatty liver comprising as an active ingredient a cell of Lactobacillus helveticus (Lactobacillus helveticus). A fatty liver preventive and / or suppressant comprising a culture of Lactobacillus helveticus as an active ingredient. A fatty liver preventive and / or suppressant comprising a culture supernatant of Lactobacillus helveticus as an active ingredient. The fatty liver preventive and / or inhibitor according to claim 2, wherein the culture is a dairy product. The fatty milk prevention and / or inhibitor according to claim 4, wherein the dairy product is any of cheese, fermented milk, and dairy lactic acid bacteria beverages. The fatty liver preventive and / or inhibitor according to any one of claims 1 to 5, wherein Lactobacillus helveticus is SBT2171 strain (FERM BP-5445). A food and drink for preventing and / or inhibiting fatty liver, comprising the fatty liver preventing and / or inhibiting agent according to claim 1. A diet for the prevention and / or suppression of fatty liver, comprising the fatty liver prevention and / or inhibitor according to any one of claims 1 to 6.

Images